-
-
-
-
-
-
-
BridgeBio Pharma (BBIO) PT Raised to $115 at Piper Sandler as 'Attruby Outperforms'
-
-
-
-
-
-
-
BridgeBio drug shows kidney benefits in heart disease study
-
-
-
-
-
-
-
BridgeBio submits FDA application for rare disease drug encaleret
-
-
-
-
-
-
-
Barclays sees a buying opportunity in this biotech stock
-
-
-
-
-
-
-
William Blair: 'we continue to view BridgeBio as a core smidcap biotech holding'
-
-
-
-
-
-
-
Mizuho sees Pfizer patent trial as the single largest catalyst for BridgeBio (BBIO) stock this year
-
-
-
-
-
-
-
Jefferies on BridgeBio Pharma (BBIO): 'Net-net, $1B+ peak sales seems reasonable'
-
459,806 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

